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ABSTRACT 
PHARMACISTS AS MID-LEVEL HEAL THCARE PROVIDERS AND THE 
CLINICAL RESULTS OF A PHARMACIST-LED DIABETES DISEASE 
MANAGEMENT PROGRAM 
Benjamin Maurice Risner 
11/28/2011 
Advancements in medical therapy have augmented resources available to 
physicians to treat disease and, because of this, spending on prescription drugs 
has doubled in the past decade. Increasingly, clinical trials are demonstrating the 
benefits of aggressive disease management in reducing morbidity and mortality. 
Physicians treating patients with chronic conditions must balance the benefits of 
combination drug therapy against the risk of adverse drug events and drug 
interactions. For instance, evidence-based practice guidelines in patients with 
diabetes and multiple comorbidities require combination therapy in order to 
reduce morbidity and mortality. Patients with polymorbidity require the attention 
of multiple physicians, further fragmenting patient care and increasing 
polypharmacy related issues. Pharmacists are increasingly recognized for 
expertise in pharmacodynamics and pharmacokinetics and have been shown to 
be beneficial when utilized in patient care. Pharmacists are in a key position to 
help physicians manage the balance between optimal disease management and 
the risks of polypharmacy. 
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Risks and Burdens of Polypharmacy 
Abiding by evidence-based standards of care for patients with a chronic 
disease often requires that healthcare providers utilize multiple medication 
therapy to maximize patient outcomes. However, pursuance of improved patient 
outcomes using multiple medication therapy predisposes patients to 
polypharmacy. Polypharmacy is generally defined as the ineffective and 
inappropriate use of multiple prescription and over the counter (OTC) 
medications to the point at which it is detrimental to patient health.[1, 2] The 
negative consequences of polypharmacy burden patients, healthcare providers, 
and third-party payers alike. 
Some common risk factors for polypharmacy include increased age, 
multiple prescribers, multiple medication therapy, institutionalization, and 
polymorbidity.[1-3] For patients diagnosed with a chronic disease with 
complicating and concurrent comorbidities, multiple medication therapy is 
necessary for adequate treatment and polypharmacy may be unavoidable.[4] For 
example, patients diagnosed with diabetes and common comorbidities such as 
hypertension and hyperlipidemia may easily require five or more medications a 
day to meet the clinical targets for each of these three conditions.[5] 
Paradoxically, the complex multidrug regimes necessary to treat patients with 
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polymorbidity may predispose them to complications associated with 
polypharmacy. [6-8] 
Side effects of polypharmacy include decreased medication compliance, 
adverse drug reactions (ADR), increased costs of care, and increased use of 
healthcare services (hospitalizations, emergency room visits, etc.). The risk of 
polypharmacy associated complications is especially great among patients that 
have concurrent comorbidities such as depreSSion, congestive heart failure, and 
are being treated by multiple healthcare providers.[1] Further, the inverse 
relationship between polypharmacy and medication compliance is routinely found 
in patients with diabetes and contributes to poor blood glucose control.[6, 7] 
The negative consequences of polypharmacy are disproportionally felt by 
the elderly as 37% of individuals over the age of 60 report regular usage of five 
or more medications.[9] The elderly are more susceptible to ADRs given their 
decreased health literacy and age-related changes in physiology that alter the 
concentration and clearance of medications.[8] ADRs cannot only be life-
threatening, they are also a significant cause of hospitalizations and increased 
costs.[1 0-12] In addition, declining cognitive function and decreased mobility can 
make adherence to medication regimens more difficult.[7] 
Effects of Mismanagement on Costs and Utilization 
Prescription drug expenditures are expected to escalate in coming years 
from $234.1 billion in 2008 to $458 billion in 2019.[13] Research and 
development by the pharmaceutical industry have increased the amount of 
improved, more effective medical therapy available to treat diseases. In addition, 
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marketing campaigns directed toward patients and physicians have increased 
the demand for these newer, more costly medications. As such, during 1999 -
2009 the number of dispensed prescriptions increased 39% along with the 
proportion of patients who reported use of multiple prescription medications.[14] 
With the increased cost and utilization of prescription medications, both patients 
and third-party payers alike stand to benefit from optimized medication therapy. 
Medication mismanagement is a substantial contributor to overall 
healthcare spending. ADRs, for instance, are a significant cause of 
hospitalizations and emergency room visits. Elderly patients are the most likely 
patient population to experience severe ADRs with the most common causes of 
hospitalization being falls, orthostatic hypotension, and delirium.[8, 15, 16] 
Although ADRs can be present at any age, their toll on the elderly population is 
greater because of their decreased physiological-reserve. Elderly patients have 
decreased muscle mass, increased body fat, decreased renal function, and 
decreased hepatic mass altering their ability to metabolize medications. Because 
of this, the clinical manifestations related to ADRs are more pronounced among 
elderly patients. Additionally, it has been determined that most hospitalizations 
involving ADRs are preventable.[16] In fact, hospitalizations often result from 
errors such as incorrect dosage, noncompliance, or omission of drug therapy.[15] 
The effects of ADRs can also be misdiagnosed by healthcare providers 
who then provide patients with additional treatment, further worsening the 
patient's polypharmacy. Urinary incontinence, weight loss, cognitive impairment, 
malnutrition, constipation, and insomnia are all associated with polypharmacy 
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and are common complaints among elderly patients but are not often recognized 
as ADRs. Due to this, patients are routinely offered medications to mitigate their 
symptoms, further worsening their polypharmacy. 
Pharmacist-led Interventions: The Case for Diabetes 
The ineffective use of medication therapy has a serious effect on the most 
vulnerable aspects of our population that ripples throughout the entire healthcare 
system. Moreover, the preventable nature of most ADRs makes further tolerance 
of their subsequent burden to both patients and third-party payers unacceptable. 
Effectively combating medication therapy mismanagement will require additional 
oversight from pharmacists who are experts in pharmacodynamics and 
pharmacokinetics. 
With the rising tide of obese and overweight Americans, the prevalence of 
diabetes and obesity related comorbidities such as hypertension and heart 
disease are expected to increase more than other chronic conditions over the 
next decade. Additionally, though diabetes is currently most prevalent in 
individuals >65 years old, the great majority of newly diagnosed cases were 
among individuals who were 45-64 years of age.[17] 
With the average age of diagnosis decreasing, the high number of 
comorbidities, and the cost of treatment increasing, diabetes is poised to become 
an even greater driver of increased health spending. The decreased amount of 
time that physicians are allotted to see patients combined with the more complex 
medication regimens needed to achieve clinical targets in patients with diabetes 
will further worsen the rates of ADRs and increase costs associated with 
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ineffective medication management.[18, 19] Primary care physicians are also 
limited in the amount of problems that they are able to address in the decreased 
amount of time they have per patient visit. Primary care physicians' time is 
divided between providing direct patient care, reviewing imaging and lab reports, 
and addressing phone calls. Though major areas of concern to the patient may 
be adequately resolved, it is likely that potential issues with polypharmacy and 
ineffective drug therapy will be overlooked.[19] 
With the increased burden to patients and third-party payers and the 
inability of healthcare providers to ensure that a patient's medication 
management is optimized, pharmacists are uniquely pOised as experts in the 
field of medication therapy management. Pharmacists' provision of medication 
therapy management (MTM) services can increase medication adherence, 
improve patient literacy, eliminate duplications in therapy, maximize medication 
therapy, and decrease the risk of ADRs. Through optimization of medication 
therapy, pharmacists can improve patient clinical outcomes and reduce costs 
associated with inadequate patient management.[20] 
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CHAPTER 2 
PHARMACISTS AS MID-LEVEL PROVIDERS 
Though traditionally pharmacists have been employed in various settings 
throughout the healthcare industry, their role as service providers has generally 
been confined to dispensing and distributing medications. As drug costs and the 
number of patients consuming multiple prescription medications increases, the 
opportunities for pharmacists to act as mid-level providers (MLP) and provide 
medication therapy management (MTM) services is growing. MTM services 
provided by pharmacists currently include comprehensive medication reviews, 
medication counseling, patient education, collaborative drug therapy 
management (CDTM), and disease management programs. 
Pharmacist provision of MTM services have been shown to improve 
patient outcomes, especially among patients on multiple medications and with 
more than one prescriber, such as ICU patients and those with chronic 
conditions.[21-23] Patients with these conditions are predisposed to increased 
morbidity and mortality associated with polypharmacy. Polypharmacy is generally 
defined as the ineffective and inappropriate use of multiple prescription and over 
the counter (OTC) medications to the point at which it is detrimental to patient 
health.[1, 2] Polypharmacy has been shown to increase the number of adverse 
drug events (ADE) and decrease medication compliance, among other things. 
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As one may imagine, the direct and indirect healthcare costs associated 
with polypharmacy and suboptimal disease management are staggering. In fact, 
the healthcare costs for a patient diagnosed with a chronic disease are five times 
greater than that of patients who aren't.[23] Many third-party payers including 
Medicaid/Medicare, self-insured employers, and private insurance companies, 
have begun utilizing pharmacist provided MTM services to reduce their overall 
healthcare costs and improve patient health.[24-28] 
As healthcare demands continue to increase, the need for pharmacists 
who can act as mid-level providers and provide MTM services will grow. Despite 
data that demonstrate the benefits of expanding the pharmacist's role in 
healthcare to include MTM services, some physicians are understandably 
anxious about the increasing profile of non-physician providers in healthcare.[29] 
However, as demands for the cost-effective provision of healthcare services 
continue to rise, pharmacists will become an invaluable resource for physicians 
and payers in optimizing medication management to achieve desired patient 
outcomes.[30] The purpose of this manuscript is to advocate for the expanded 
role of pharmacists in the clinical setting and explain that their inclusion in 
providing care benefits patients and physicians alike. 
Background 
In the 1950s, pharmacists began to expand their scope of practice beyond 
the dispensing and distribution of medication, as pharmacists employed with the 
Indian Health Service (IHS) pioneered the concept of clinical pharmacy and 
pharmaceutical care. When IHS clinics were first established, many were located 
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in remote areas of the country with limited resources, and an overwhelming need 
for medical care necessitated that pharmacists playa larger role in the care of 
patients.[31] As federal employees, IHS pharmacists were not limited by 
individual state laws regulating their scope of practice.[32] As such, IHS 
pharmacists were often utilized to provide comprehensive medication reviews, 
screen patients for conditions such as diabetes and hypertension, and to help 
coordinate care. The expanded, collaborative relationships that the IHS 
pharmacists had with physicians and other healthcare providers also extended to 
the inpatient setting as pharmacists would round with physicians to provide 
guidance on questions that arose regarding medication. 
Given the cultural differences and limited education that were common 
among the patient population, collaboration among providers was essential to 
ensUre that patients understood their medical condition and remained compliant 
with their medications. To help facilitate this, the IHS pharmacists had access to 
their patient's full medical records, which allowed the pharmacists to make sure 
that patients were receiving optimal drug therapy. Also, because patients often 
visit their pharmacist more often than their physician, pharmacists were able to 
encourage and facilitate follow-up with the primary care providers.[33, 34] 
Aside from the IHS, the Veteran's Health Administration (VHA) has also 
utilized pharmacists in expanded clinical roles, working as mid-level providers. 
Building on the experiences and success with the IHS, the VHA further expanded 
the clinical roles of pharmacists and furthered their incorporation into the primary 
care system. The VHA established several specialty clinics where pharmacists, 
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with additional training in the treatment of specific conditions, treated patients 
under a collaborative drug therapy management (CDTM) agreement with the 
patient's prescriber. The CDTM established protocols under which the 
pharmacist could initiate, alter, or discontinue therapy to achieve optimal disease 
management. The clinics specialized in areas such as diabetes, hypertension, 
nephrology, anticoagulation, and HIV. As an example, if a patient at the 
anticoagulation clinic was determined to have a sub-therapeutic INR, the 
pharmacists had the autonomy to alter the patient's medication to achieve a 
therapeutic INR.[35, 36] 
In 1996, the city of Asheville, North Carolina, a self-insured employer, 
found that chronic diseases such as diabetes were the leading drivers behind its 
increasing healthcare costs. Previously, pharmacist-led clinics were provided by 
integrated health systems such as the VHA and IHS. The Asheville Project, 
however, established pharmacist-led diabetes clinics in community pharmacies 
and used incentives such as waived co-pays for diabetes medications and free 
testing supplies to ensure patients remained engaged in the program. 
The Asheville Project sought participation and advice from local 
physicians, dieticians, and area pharmacists in development and implementation 
of the pharmacist-led intervention. The pharmacists in the Asheville Project met 
with the patients regularly to address blood glucose levels, lipids, and weight 
management. The pharmacist would work with the patient to resolve any 
medication issues or treatment questions that they had. The pharmacist would 
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keep documentation of the visit and send the patient's physician a note detailing 
the visit and any areas of concern that they felt needed to be addressed.[25] 
Aside from popularity among patients and physicians, the pharmacist-led 
intervention in the Asheville Project resulted in consistent improvements in the 
patient's HbA 1 c and serum lipid values over 14 months of enrollment.[25] As a 
result of the intervention, the patient population also had lower healthcare costs 
as their clinical improvement led to decreased utilization of costly healthcare 
services such as hospitalizations and emergency room visits. 
The success of the Asheville Project has since been translated into 
pharmacist-led disease management programs being established by other third-
party payers across the country. For instance, Medicare Part D began providing 
MTM services to patients with a high utilization of services as a way to reduce 
medication related costs.[37] In addition to Medicare, many state Medicaid 
programs have also started to utilize pharmacists' MTM services.[38] For 
instance, in 2005 the state of Minnesota passed legislation that would allow 
pharmacists to be reimbursed through the state's Medicaid budget for MTM 
services provided to patients with chronic illnesses and on multiple medications. 
Within the first year of MTM implementation, pharmacists were able to identify 
and correct numerous medication errors and the number of diabetic patients 
enrolled in the program who had optimal control was greater than the state 
average.[28] Similar Medicaid provided MTM programs have been developed in 
states like Iowa, Missouri, and North Carolina.[27, 39] 
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Unique Among Mid-Level Providers 
Mid-level providers are generally classified as non-physician practitioners 
(NPP) that provide direct patient care in both the hospital and outpatient setting, 
often acting in the role of a "physician extender." Mid-level providers fulfill a 
variety of roles in healthcare and include nurse practitioners (NP), certified nurse 
midwives (CNM), physician's assistants (PA), and clinical nurse specialists 
(CNS). While the training and certification requirements of each mid-level 
provider varies, in general, mid-level NPP's have two years of master's level 
training, focusing on the provision of basic clinical services such as diagnosing, 
examining, and treating patients.[40] 
Limitations on the mid-level, NPPs scope of practice vary by state. 
However, in most states they are granted prescriptive authority and allowed a 
broad range to practice within their ability. The variety of services offered by 
NPPs in both the hospital and outpatient setting include physical exams, ordering 
and interpretation of diagnostic exams, and minor, noninvasive procedures. 
However, mid-level NPPs are reimbursed at a lower rate by Medicare than 
physicians because they are confined, by virtue of their training, to providing care 
for less complex patients.[40, 41] 
Pharmacists differ from other mid-level NPPs in a number of ways 
including education, training, and scope of practice. The American Association of 
Colleges of Pharmacy (AACP) mandated in 1990 that Doctorate of Pharmacy 
(PharmD) would be the first professional degree offered by Schools of 
Pharmacy.[42] Pharmacists would still undergo rigorous training regarding the 
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appropriate usage, pharmacology, and interactions of drugs as one might expect. 
However, pharmacy students are now offered a great deal of clinical training in 
patient care and communication as a part of their PharmD program. Also, 
pharmacists, unlike other mid-level NPPs, have the option of completing a 
residency, becoming certified, and focusing their careers in subspecialty areas 
such as nutrition, oncology, HIV, critical care, and others.[42] 
Given the extent of their training, pharmacists now have a vast array of 
knowledge not only on the mechanisms of various drugs but also on how they 
interact with each other and the human body to cure a patient. Because their 
training is so extensive, pharmacists possess a unique skill set that is not shared 
with other mid-level NPPs or even physicians.[41] Given the potential benefit that 
pharmacists can provide to both patients and physicians, their level of 
involvement in patient care will only continue to grow. 
Pharmacists' role as healthcare providers has largely been defined by the 
dispensation and distribution of medications. Increasingly, however, automated 
filling systems and pharmacy technicians are dispensing medications under 
pharmacist supervision. While this transition has made pharmacies more efficient 
and helped control costs, it has left pharmacists seeking a way to expand their 
ability to provide services to patients. In addition, now that all pharmacists 
entering into practice have obtained their PharmD, many feel that their training 
and abilities are being underutilized. 
As stated earlier, MTM contains a broad range of cognitive services that 
pharmacists provide beyond dispensing and distributing medication. Some of the 
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services that pharmacists offer under MTM include chronic disease 
management, immunizations, medication surveillance, comprehensive 
medication reviews, and pharmacotherapy. These MTM services are being 
performed by pharmacists in a variety of both settings including hospitals and 
oL!tpatient clinics.[43, 44] Provision of MTM services has shown increased 
medication compliance, optimization of therapeutic regimens, and a decrease in 
adverse drug events.[44] Patient satisfaction with the care they receive from 
pharmacists providing MTM services such as chronic disease management is 
generally positive. 
Benefit of MTM Services 
Polypharmacy is a condition that is prevalent in individuals with chronic 
diseases and the elderly. The elderly population consumes almost 30% of the 
prescription medications dispensed in the United States and, on average, take 
4.5 prescription medications and two over the counter (OTC) medications.[45] 
Individuals with multiple chronic conditions such as diabetes, congestive heart 
failure, and capo, are also likely to be on multiple prescription and OTC 
medications. Polypharmacy increases the likelihood that a patient will experience 
an AOE or other medication related event requiring a hospitalization and reduces 
patients' adherence to medication regimens resulting in suboptimal disease 
management. 
Given the substantial cost increase that is associated with polypharmacy, 
MTM services can be particularly beneficial. Pharmacists are able to perform 
comprehensive medication reviews and minimize the possibility of AOEs while 
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simultaneously optimizing the patient's medication management.[46] In addition, 
a pharmacist review of a patient medication list can lead to discontinuation of 
ineffective or duplicated medication therapy. Given the high cost of prescription 
medications and the outcomes that can be associated with ADEs, MTM services 
are an essential component to the proper management of patients. 
MTM Implementation 
In 2003, the Medicare Prescription Improvement and Modernization Act 
(MMA) became signed into law, providing increased prescription drug coverage 
for individuals enrolled in Medicare. Beginning in 2006, the Center for Medicare 
Services (CMS) began requiring providers of Medicare Part D (PDP) to provide 
MTM services as a way to save costs, reduce drug interactions and ADEs, and 
optimize medication management.[40] The MTM services focused on identifying 
and resolving medication related issues and providing comprehensive medication 
reviews for patients on multiple Part D medications with multiple chronic 
conditions whose drug costs were greater than $4,000. After realizing a 
significant savings in drug costs and reductions in medication related errors, 
CMS has recently recommended an expansion of their MTM services and has 
reduced the cost threshold for eligible patients to $3,000.[40] 
Though MTM services have been shown to produce better patient 
outcomes and reduce costs, many third-party payers are still not covering these 
services. In addition, pharmacists cite an inadequate representation of MTM 
services in the current medical coding system as a Significant barrier to obtaining 
payment for their services.[47, 48] Also, many third-party payers are not fully 
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recognizing MTM services as separate from dispensing services and, because of 
this, pharmacists are unable to bill for their services. Pharmacists are also not 
recognized by third-party payers as healthcare providers in the same way that 
NP, PA, and CPSs are.[48] Because of this, pharmacists are often not able to 
bill directly for their services and instead must bill MTM services as incidental to 
physician services.[40] 
Up until recently, MTM services provided by pharmacists were rare 
outside of large, academic settings. Pharmacists working in community-based 
retail pharmacies still spend a great deal of their time dispensing medications to 
patients. In order to fully implement MTM services, pharmacies would have to 
invest more resources into hiring pharmacists and pharmacy technicians. 
Pharmacists would also have to find a way to document and bill for their services 
and establish a greater amount of communication among physicians in their 
area.[49] Currently, with many different health information technology (HIT) 
systems being utilized across the country there is no standardized billing and 
documentation system which further hinders pharmacists' ability to provide MTM 
services. 
In order for patients, providers, and payers to receive the greatest amount 
of benefit from MTM services, there must be cooperation and collaboration 
among all of a patient's healthcare providers. Most successful MTM 
implementation has occurred in environments that are conducive to collaboration 
among the different healthcare providers and integration of healthcare services. 
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Most payers find it necessary to include incentives for patients to remain 
engaged with their pharmacist.[28] While it is true that most individuals visit their 
pharmacist more than their physician, some pharmacists have complained of 
trouble getting patients to follow up after an initial visit. However, financial 
incentives such as waived copayments for medications can entice patients to 
remain engaged.[50] 
MTM Future 
Included in the Affordable Care Act (ACA) was a provision for the 
development of Accountable Care Organizations (ACO) as a new 
comprehensive, patient-centered method delivering patient care that rewards 
healthcare providers for the quality of the care they provide. ACOs are 
accountable to patients and payers for the cost, quality, and efficiency of the care 
that they provide.[51] Since the current fee for service method of paying 
healthcare increases utilization without increasing quality, it is likely that a 
capitation system of payment will be adopted with provisions for shared 
savings.[52] The capitation method of payment provides a lump sum for 
healthcare services whether patients utilize services or not. Patients with chronic 
diseases who have been enrolled in MTM services have shown a decrease in the 
number of ER visits and hospitalizations. Taking the highest risk individuals 
enrolled in a health plan and enrolling them in a pharmacist-led MTM service 
chronic disease management is a proven method of reducing costs and 
improving patient outcomes.[52] 
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Pharmacists can also figure prominently in Patient Centered Medical 
Homes (PCMH). PCMH is a practice model that places the primary care 
physician as the leader of a patient's healthcare team.[53] Aside from the PCMH 
serving as a patient's gateway into the healthcare system, it will also provide 
patients with disease management and other services that are not currently 
offered in most community primary care offices. Having access to a patient's full 
medical record, pharmacists will be able to collaborate directly with physicians in 
the PCMH to maximize patient outcomes.[46] In addition, given the likelihood that 
capitation and shared savings will become the preferred form of payment for 
patient care in the future, pharmacist provision of MTM services will be essential 
to control costs and improve patient outcomes.[54] 
From the data presented, it can be clearly seen that pharmacists as mid-
level providers of MTM services have the potential to benefit patients, payers, 
and providers. Chronic disease management programs that are administered by 
pharmacists have been shown to significantly reduce costs to third-party payers. 
Aside from the savings realized immediately by payers, it is hoped that better 
management of patients diagnosed with diabetes, for instance, will produce long-
term cost savings by reducing complications that result from poorly managed 
blood glucose levels such as renal failure. 
Further recognition of pharmacists as mid-level providers will require a 
greater amount of understanding by physicians and payers as to the benefits of 
providing MTM services.[37] In addition, physicians and other providers are 
currently paid under a fee-for-service arrangement whereby they are paid more 
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for additional services than they provide. Until healthcare providers are provided 
an incentive to maximize preventative services and emphasis well ness among 




CLINICAL RESULTS OF A PHARMACIST-LED DIABETES DISEASE 
MANAGEMENT PROGRAM 
The impact of chronic diseases on healthcare costs has become an 
increasingly important topic. Indeed, the impact of only five or six chronic disease 
including diabetes, hypertension, cardiovascular disease (CVD), asthma, chronic 
obstructive pulmonary disease (COPD), and musculoskeletal disease account for 
75% of the annual health costs in the U.S.[55] Medical advances over the last 
half of the twentieth century have provided an abundance of new opportunities to 
better treat and manage disease. These advances have not only improved the 
quality of life for many people but have also increased the life expectancy for 
individuals suffering from chronic diseases. However, the rising life expectancy 
coupled with the advanced medical technology required for long-term care of 
patients diagnosed with a chronic disease has led to an exponential growth in the 
cost of healthcare.[55, 56] The increased cost of healthcare provides a 
significant barrier to those seeking medical treatment while also hampering 
economic growth and contributing to inflation nationwide.[56] Moreover, a recent 
survey of CEOs revealed that employee healthcare places the greatest cost 
pressure on American businesses.[57] 
Diabetes, primarily type II diabetes, stands out as a particularly significant 
driver for healthcare spending.[17] Diabetes is also one of the chronic diseases 
19 
where the annual rate of increase shows little sign of abating.[58] The increasing 
incidence of diabetes has been closely associated with the emergence of the 
obesity epidemic in America. Among the reasons for the higher costs associated 
with diabetes is that individuals diagnosed with the disease are also placed at an 
increased risk for comorbidities such as hypertension, renal failure, retinopathy, 
neuropathy, and peripheral vascular disease. Improved glucose control, and 
more highly aligned healthcare, have been shown to decrease an individual's risk 
for acquiring these comorbidities.[17, 50] 
The University of Louisville (Louisville, KY), which self-funds the 
healthcare benefits for its employees, began to parse their healthcare spending 
into chronic disease categories in 2009. At that time, an initial analysis suggested 
that almost 20% of the total health care expenditures were associated with an 
enrollee having a diagnosis of diabetes. Faced with this rise in cost and the 
significant morbidity and mortality that are associated with the disease, the 
University of Louisville (UofL) human resources leadership decided to seek 
meaningful solutions centered around diabetes with the stated goals of improving 
the health of the diabetic enrollees and decreasing the rate of the annual rise in 
the healthcare costs associated with this population. 
While telephonic based programs have traditionally been used in the care 
of patients and enrollees with chronic conditions such as hypertension, diabetes, 
hyperlipidemia, and depression, the results have been generally modest.[59] 
UofL decided, however, to initiate a pharmacist-led program of medication 
therapy management (MTM) in a high-touch environment, based on the Asheville 
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Project.[50] This program, created in 1996 by the City of Asheville, North 
Carolina used a pharmacist-led intervention program to help it control the rising 
healthcare costs it faced as a self-insured employer. This manuscript reports the 
initial results of a high-touch, pharmacist-led program, diabetes centered disease 
management program at the University of Louisville. 
Methods 
In January 2010, a healthcare claims analysis of the employees enrolled 
in the University of Louisville's health benefit plan suggested the presence of 424 
diabetics. All healthcare claims analyzed and identification of members with 
diabetes was performed by a separate legal entity using a Business Associate 
Agreement. Raw claims data were collected through the University of Louisville's 
benefit consultant, Aon Corporation ™ and data analytics were provided by Verisk 
Analytics®. Members were determined to have diabetes if they had two or more 
outpatient claims with diagnosis of diabetes or one inpatient claim with a 
diagnosis of diabetes from January 2009 to December 2009. Once the database 
was created, a Paretto curve was created were enrollees were stratified 
according to amount (dollars) of claims paid in the plan year. Beginning in March 
2010, 120 individuals with the highest insurance claims were initially recruited for 
enrollment; later the Diabetes Disease Management Program (DDMP) became 
available to all UofL Healthcare members diagnosed with type I or II diabetes. 
Notification of eligibility and recruitment were done with direct mailings and 
informative luncheons. 
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To participate, the enrollees met one-on-one with the designated 
pharmacist for an initial visit and signed a "contract" indicating their willingness to 
meet regularly with a pharmacist and the understanding that they must remain 
active in the program in order to continue to receive the benefit incentives. As a 
part of the DDMP, all enrollees were required to meet with a diabetic educator for 
two hours of diabetic training and to meet with a nutritionist for two hours of diet 
counseling. The pharmacists who participated in the UofL DDMP received 
additional training in the care of diabetic patients including the American 
Association of Diabetes Educators Core Concepts course. 
Table 1 
Association of American Diabetes Educators Core Concepts Course 
Objectives for Providers 
1 Pathophysiology, Epidemiology, and Guidelines for Diabetes Care 
• ensures providers have understanding of pathogenesis and clinical 
manifestations of diabetes 
2 Culturally Competent Supportive Care Across Lifespan 
• compassionate and effective communication with patients 
3 Teaching and Learning Skills 
• focuses on effective methods of providing information to patients 
4 Self- Management Education 
• how to empower patients to manage their diabetes 
5 Program and Business Management 
• skills to efficiently and effectively provide services to patients 
22 
During the initial visit, the pharmacists recorded medical history, current 
medications, current primary and specialist physicians, and attempted to discern 
the current level of medical and pharmaceutical understanding of the enrollee as 
it pertained to diabetes. Systolic and diastolic blood pressure was measured, 
height and weight were recorded, and BMI calculated. Laboratory values 
consisting of a Lipid Panel, Basic Metabolic Panel (serum electrolytes, blood 
glucose, creatinine), and Urinalysis (micro albuminuria) were obtained as well as 
a point of care glycosylated hemoglobin (HbA1c). In general, the goal was HbA1c 
:::;;7%. 
Diabetics with target glucose control (e.g., HbA1c :57%) were scheduled 
for follow-up at three-month intervals. However, diabetics with an HbA1c of 7-8% 
and >8% were given suggested lifestyle and medication changes and scheduled 
for a follow-up visit In two months and one month, respectively. The pharmacist 
also performed a foot exam at each visit to check for signs of neuropathy or 
vascular disease and checked the patient's vaccination status. Ophthalmology, 
endocrinology, vascular surgery, cardiology, podiatry, and dental referrals were 
provided if needed. After each visit a letter was sent by the pharmacist to the 
patient's primary physician detailing the encounter and any concerns. 
To encourage enrollment and as a major incentive for ongoing 
participation, enrollees received free diabetes testing supplies (including 
glucometers and test strips) and co-payments for hypertensive, cholesterol 
lowering, and diabetic medications were waived at the point of sale. Thus, 
income should not be a barrier to access for critical medications. 
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As of October 2011, 210 enrollees were contracted into the DDMP. 
Seventy-seven (77) of the 210 enrollees have been enrolled for a minimum of 12 
months and constitute the dataset for this report. The patients' charts were 
reviewed under an IRB approved protocol and clinical data including HbA 1 c, 
blood pressure, and BMI were analyzed. 
By measuring the HbA 1 c every three months and abiding by other 
evidence-based practice guidelines, providers were also helping to reduce the 
patient's Care Gap Index (CGI). The CGI is a proprietary measure calculated by 
Verisk Analytics® that quantifies a patient's deviations from evidence-based 
treatment guidelines. Ultimately, the CGI gives providers a more comprehensive 
view of a patient's health status and compliance with recommended treatments. 
The data were then analyzed by conducting a two-way ANOVA with multivariate 
analysis using SPSS 20.0.0 statistical software. 
Results 
To date, 77 individuals have been enrolled for at least 12 months. Of 
these, 53 were Caucasian, 22 African-American, and 2 Asian. The mean age 
was 57 years old. There were 52 females and 25 males. Also, 72 had DM2 and 5 
had DM1. 
A statistically significant reduction in the HbA1c was observed among the 
77 enrollees in this high-touch diabetes management program. After 12 months 
of enrollment, the mean HbA1c was reduced from 7.9% ± 0.2% to 6.9% ± 0.1% 
(p < 0.001) with a goal HbA1c being 7.0%. Figure 1 shows the average HbA1c 
among the 77 enrollees at 0,3,6,9, and 12 months of enrolling in the DDMP. 
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Figures 2, 3, and 4 show the changes in systolic blood pressure (SBP), diastolic 
blood pressure (DBP), and BMI, respectively at months 0 and 12. 
8 7.9% 
(p < 0.00 1) 
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Figure 1. Decrease in the mean HbA1c at the 0,3,6,9, and 12 month visits. 
Overall, the mean HbA1c experienced a statistically significant decrease 























Figure 2. Decrease in the mean systolic blood pressure (SBP) at the 0 and 
12 month visits. Overall, the mean SBP experienced a non-statistically 
significant decrease from 140 ± 2 at month 0 to 137 ± 2 at month 12. Values 
















Figure 3. Decrease in the mean diastolic blood pressure (DBP) at the 0 and 
12 month visits. Overall, the mean DBP experienced a non-statistically 
significant decrease from 75 ± 1 at month 0 to 74 ± 2 at month 12. Values 















Figure 4. Decrease in the mean basal metabolic index (BMI) at the 0 and 12 
month visits. Overall, the mean DBP experienced a non-statistically 
significant increase from 35.8 ± .95 at month 0 to 36 ± .95 at month 12. 
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Figure 5. Decrease in the mean care gap index (CGI) at the 0 month (pre-
enrollment) and 12 month (post-enrollment) visits. Overall, the mean CGI 
experienced a statistically significant increase from 14.2 at month 0 (pre-
enrollment) to 5.6 at month 12 (post-enrollment). N = 77. 
Discussion 
The purpose of this study was to determine if a pharmacist-led DDMP 
would be successful at improving the health of enrollees diagnosed with 
diabetes. As such, the primary variables analyzed for this study were HbA 1 c, 
SBP, DBP, BMI, and CGI. The primary finding of this study was a significant 
improvement in blood glucose control and increased compliance; however, there 
was no significant improvement in SBP, DBP, or BMI. 
Currently, American Diabetes Association (ADA) recommendations are 
that patients maintain their HbA1c :::;7%.[5] Despite the fact that all the enrollees 
were being seen by a primary care physician, their average HbA 1 c upon 
enrollment was 7.9%. Reasons for elevated HbA1c levels included medication 
noncompliance, gaps in knowledge of diet and medication, improper diet, 
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infrequent blood glucose testing, and poor physician follow-up. Improvement of 
the enrollee's HbA 1 c was seen within the first three months of enrollment and 
was maintained throughout the 12-month period. In addition to meeting with the 
diabetes educator and nutritionist near the time of enrollment, the initial 
pharmacist visit was also effective at identifying and resolving issues that led to 
the increased HbA 1 c in a timely manner. At each meeting with the pharmacist, 
individual factors that could have led to an elevated HbA 1 c were discussed with 
the enrollee and individual treatment goals were set. If needed, the pharmacist 
provided recommendations to the enrollee's primary care physician as to any 
medication changes that would improve the patient's blood glucose control. 
As stated, the CGI is a proprietary measure by Verisk Analytics® that 
utilizes each enrollee's medical claims data to quantify their deviations from 
evidence-based diabetes treatment guidelines. For the DDMP, the pharmacist 
tried to ensure that enrollees were achieving clinical guidelines established by 
the ADA and other professional organizations. For instance, the pharmacist 
ensured that patients were receiving annual physical exams, being seen 
regularly by a podiatrist, remained up to date on all of their vaccinations, and 
received annual retinal exams. By coordinating among various providers, the 
pharmacist made sure that enrollees were compliant with all recommended 
clinical guidelines for the treatment of diabetes. In addition, the pharmacist was 
also able to review the patient's prescription medication lists and minimize 
chances of a patient suffering from an adverse drug event (ADE). This attention 
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to detail is reflected in the decrease of the average CGI from 14.2 to 5.2 over the 
12-month enrollment. 
Also, Figure 5 demonstrates that patients with the highest care gaps at 
enrollment enjoyed some of the largest reductions in CGI thanks to pharmacist 
adherence to best practice guidelines. Though the way in which the CGI is 
calculated changes with alterations in recommended guidelines of best practice, 
it does provide us with an indication of how successful the DDMP has been in 
increasing the enrollee's treatment compliance. 
Collaboration among the various stakeholders involved was essential to 
ensuring that our DDMP achieved the desired clinical outcome. Specialist 
physicians at UofL such as nephrologists, podiatrists, and ophthalmologists were 
recruited to become involved in the DDMP and to provide care for patients with 
possible diabetic complications. To facilitate participation in the program, 
administrators met with each specialist physician and asked them to provide 
clinical criteria that the pharmacist could use in determining whether a referral to 
their clinic was appropriate. Allowing the various providers an opportunity to have 
input into the design of the program and to determine how their specialty would 
be represented helped to ensure that each specialist's clinical boundaries were 
respected and allowed us to maintain support for the DDMP. 
Enrollees were also provided incentives to remain engaged in the DDMP, 
which created more interest and participation than would have otherwise been 
expected. Effective provision of disease management services requires 
longitudinal care and it is essential that enrollees continue to feel the benefits of 
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the program so that they remain actively involved. Providing incentives helped 
ensure that the patients remained in the DDMP even after their HbA 1 c was at 
goal. Follow-up appointments with the pharmacist were scheduled so as to 
coincide with the date of the patient's next medication refill in order to make 
ongoing participation as convenient as possible. In addition, we helped to assure 
continuity of care for the enrollees by only employing a handful of pharmacists to 
provide clinical services. By maintaining a high retention of enrollees, we helped 
to ensure that their clinical progress was being maintained and that any deficits in 
their care were handled in a timely manner. 
As third-party payers are increasingly looking for proven methods to 
reduce healthcare costs, the utilization of pharmacists as mid-level providers of 
MTM services will increase. There have been numerous pharmacist-led diabetes 
interventions introduced by third-party payers acrosS the country with similar 
success in improving the patient's diabetes disease management.[24, 50] In fact, 
Medicare requires providers of its Part 0 prescription drug plan to offer MTM 
services to patients who take five or more medications and whose prescription 
drug costs exceed a certain threshold.[28, 37, 38] Given the increasing burden 
that prescription medication costs place on third-party payers, pharmacists' 
expertise in pharmacotherapy will be increasingly called upon to optimize 
medication therapy and to minimize errors and duplications in treatment. 
The UofL DDMP demonstrated that a high-touch intervention led by 
pharmacists can be successful at improving clinical outcomes and adherence to 
treatment guidelines for patients diagnosed with diabetes. This collaborative 
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method of healthcare delivery could be duplicated and adapted to provide 




As healthcare costs continue to grow at an unacceptable rate and 
physicians are increasingly pressured to manage complex patients in a limited 
amount of time, the need for pharmacist provision of MTM services will grow as 
well. This thesis demonstrated the utility of a high-touch, pharmacist-led diabetes 
disease management program in achieving recommended clinical outcomes for 
patients with diabetes. The significant reduction in HbA 1 c was achieved after an 
average three months of enrollment and sustained throughout the duration of the 
DDMP. Moreover, the pharmacist-led DDMP was significant in that it successfully 
reduced the average CGI of patients enrolled in the DDMP for 12 months. By 
increasing the patient's adherence to evidence-based guidelines, it is hoped that 
our patient population would experience decreased complications and associated 
healthcare expenditures over the long term. 
Future studies could focus on expansion of the DDMP to include 
implementation of a hypertension focused intervention. Additionally, the DDMP 
could implement interventions focused on other common comorbidities among 
diabetics such as hyperlipidemia. Successful pharmacist-led hypertension and 
hyperlipidemia interventions were successfully implemented in the Asheville 
Project.[60] Given that these conditions are highly prevalent among diabetics, a 
substantial reduction in morbidity and mortality could be achieved by ensuring 
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that patients enrolled in the DDMP are adhering to evidence-based guidelines in 
these areas. Further, pharmacist interventions could be designed for other 
chronic conditions with high rates of polypharmacy such as congestive heart 
failure and COPD. 
As the demand for healthcare continues to rise, the pharmacist provision 
of MTM services will continue to grow in popularity as third-party payers seek to 
ensure the efficient and effective use of costly medications. Patients will also 
benefit tremendously from the reduced morbidity and mortality that result from 
stricter adherence to evidence-based clinical guidelines for diseases such as 
diabetes. Pharmacist provision of MTM services will be essential to providing 
comprehensive healthcare as the number of patients requiring complex 
medication therapy continues to grow. 
Future studies could focus on expansion of the DDMP to include 
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